贝伐珠单抗治疗三阴性乳腺癌相关进展*

Progress on using bevacizumab in treating triple- negative breast cancer

摘要: 三阴性乳腺癌是指雌激素受体（estrogen receptor ，ER）、孕激素受体（progesterone receptor，PR）及人类表皮生长因子受体- 2（human epidermal growth factor receptor-2，HER-2）均为阴性的乳腺癌。三阴性乳腺癌患者因不具备内分泌治疗和抗HER-2治疗的靶点，因此在治疗方面以化疗为主。贝伐珠单抗作为一种针对人血管内皮生长因子（vascular endothelial growth factor，VEGF）的单克隆抗体，在三阴性乳腺癌中是仅有的使用比较广泛的靶向治疗药物。本文将就贝伐珠单抗在三阴性乳腺癌的新辅助治疗、辅助治疗和晚期一线、二线治疗方面的相关研究进行综述。

Abstract: The characteristic of triple-negative breast cancer (TNBC) is defined as ER-negative, PgR-negative, and HER 2-nega-tive. Chemotherapy is primarily used to treat TNBC because TNBC patients do not have the targets of endocrine therapy and HER- 2 therapy. Bevacizumab is the only widely used target drug in TNBC and acts as a monoclonal antibody target on human vascular endo -thelial growth factor. This article provides a review on the progress of using bevacizumab in neo- adjuvant therapy, adjuvant therapy, and first- and second-line treatment of TNBC.